Research
Hormonal
Finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces cardiovascular and renal risks in patients with type 2 diabetes and chronic kidney disease.
If you have type 2 diabetes and kidney disease, adding finerenone to your current treatment can significantly lower your risk of heart problems and kidney failure. It is designed to avoid the side effects of older medications in its class.
StrongSupportsHIGH confidence
FIDELITY study found that finerenone significantly reduced the risk of composite cardiovascular outcome by 14% and the risk of a composite renal outcome by 23% compared to placebo.
Why this rating
Based on phase 3 trials (FIGARO-DKD, FIDELIO-DKD) and a pre-specified meta-analysis (FIDELITY).
Source
Promising outcomes from latest landmark diabetes trials: tirzepatide and finerenone in the spotlight
Lakshmi Sankaran et al. · Practical Diabetes · 2023
DOI 10.1002/pdi.2432
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide (a dual GIP/GLP-1 receptor agonist) administered weekly via subcutaneous injection significantly reduces HbA1c and body weight in adults with type 2 diabetes compared to placebo, semaglutide, and insulin.Strong
- Semaglutide (2.4mg weekly) leads to significant weight loss in adults with obesity or overweight, and maintaining treatment prevents weight regain.Strong
- Incretin-based treatments (semaglutide, dulaglutide) are effective and safe in adolescents with obesity or type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →